1. The compound, which is a deuterium-enriched 4-hydroxy-5-methoxy-N, 1-dimethyl-2-oxo-N - [(4-trifluoromethyl) phenyl] -1,2-dihydroquinoline-3-carboxamide, having an enrichment deuterium in the amide-N-methyl group of at least 70%； or its salt with a pharmaceutically acceptable organic or inorganic cation. 2. A compound according to claim 1, wherein said enrichment in deuterium is at least 90%. The compound according to claim 1, having the formula (I), wherein is H or a pharmaceutically acceptable organic or inorganic cation； and R, R and R are independently selected from H and D； and CRRR has a total deuterium enrichment of at least 70% .4. The compound according to claim 3, wherein each of R, R and R has a deuterium enrichment of at least 90%. A compound according to claim 1, wherein the pharmaceutically acceptable cation is selected from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. The compound of claim 2, wherein the pharmaceutically acceptable cation is selected from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. A compound according to claim 3, wherein the pharmaceutically acceptable cation is selected from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. The compound according to claim 4, wherein the pharmaceutically acceptable cation is selected from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. A compound according to any one of claims 1 to 8 for use as a medicine. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8.11. The compound according to any one of claims 1 to 8 for use in the prevention or treatment of disorders1. Соединение, которое представляет собой обогащенный дейтерием 4-гидрокси-5-метокси-N,1-диметил-2-оксо-N-[(4-трифторметил)фенил]-1,2-дигидрохинолин-3-карбоксамид,
